MedTrace Logo

Tolerability of Grazax-R in Children

NCT00298701 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2006-05-04

No results posted yet for this study

Summary

This trial is performed to assess whether the Grazax-R treatment is safe to use in children aged 5-12 years.

Conditions

  • Allergy

Interventions

BIOLOGICAL

ALK Grass tablet

Sponsors & Collaborators

  • ALK-Abelló A/S

    lead INDUSTRY

Principal Investigators

  • Kim Simonsen, MD · ALK-Abelló A/S

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
5 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Completion
2006-04-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00298701 on ClinicalTrials.gov